145 related articles for article (PubMed ID: 19507339)
21. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats.
Jesmin S; Sakuma I; Hattori Y; Kitabatake A
Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):2021-6. PubMed ID: 12958045
[TBL] [Abstract][Full Text] [Related]
22. Matrix modulation and heart failure: new concepts question old beliefs.
Deschamps AM; Spinale FG
Curr Opin Cardiol; 2005 May; 20(3):211-6. PubMed ID: 15861009
[TBL] [Abstract][Full Text] [Related]
23. Loss of PI3Kγ enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress.
Guo D; Kassiri Z; Basu R; Chow FL; Kandalam V; Damilano F; Liang W; Izumo S; Hirsch E; Penninger JM; Backx PH; Oudit GY
Circ Res; 2010 Nov; 107(10):1275-89. PubMed ID: 20847309
[TBL] [Abstract][Full Text] [Related]
24. Lentivirus mediated IL-17R blockade improves diastolic cardiac function in spontaneously hypertensive rats.
Liu W; Wang X; Feng W; Li S; Tian W; Xu T; Song Y; Zhang Z
Exp Mol Pathol; 2011 Aug; 91(1):362-7. PubMed ID: 21530504
[TBL] [Abstract][Full Text] [Related]
25. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
[TBL] [Abstract][Full Text] [Related]
26. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
Janssens S; Lijnen HR
Cardiovasc Res; 2006 Feb; 69(3):585-94. PubMed ID: 16426591
[TBL] [Abstract][Full Text] [Related]
27. Ontogeny of enhanced decorin levels and distribution within myocardium of failing hearts.
Medeiros DM; Velleman SG; Jarrold BB; Shiry LJ; Radin MJ; McCune SA
Connect Tissue Res; 2002; 43(1):32-43. PubMed ID: 12180266
[TBL] [Abstract][Full Text] [Related]
28. Altered degradation of extracellular matrix in myocardial remodelling: the growing role of cathepsins and cystatins.
Díez J
Cardiovasc Res; 2010 Sep; 87(4):591-2. PubMed ID: 20573730
[No Abstract] [Full Text] [Related]
29. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis.
Heeneman S; Cleutjens JP; Faber BC; Creemers EE; van Suylen RJ; Lutgens E; Cleutjens KB; Daemen MJ
J Pathol; 2003 Jul; 200(4):516-25. PubMed ID: 12845619
[TBL] [Abstract][Full Text] [Related]
30. Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors.
Kassiri Z; Khokha R
Thromb Haemost; 2005 Feb; 93(2):212-9. PubMed ID: 15711735
[TBL] [Abstract][Full Text] [Related]
31. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.
Spinale FG
Physiol Rev; 2007 Oct; 87(4):1285-342. PubMed ID: 17928585
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers of apoptosis, inflammation, and cardiac extracellular matrix remodelling in the prognosis of heart failure.
Osmancik P; Louckova A
Kardiol Pol; 2017; 75(4):295-305. PubMed ID: 27747854
[No Abstract] [Full Text] [Related]
33. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
Vanhoutte D; Heymans S
J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
[TBL] [Abstract][Full Text] [Related]
34. Membrane-associated matrix proteolysis and heart failure.
Spinale FG; Janicki JS; Zile MR
Circ Res; 2013 Jan; 112(1):195-208. PubMed ID: 23287455
[TBL] [Abstract][Full Text] [Related]
35. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
Goetzenich A; Hatam N; Zernecke A; Weber C; Czarnotta T; Autschbach R; Christiansen S
J Heart Lung Transplant; 2009 Oct; 28(10):1087-93. PubMed ID: 19782292
[TBL] [Abstract][Full Text] [Related]
36. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction.
Westermann D; Lindner D; Kasner M; Zietsch C; Savvatis K; Escher F; von Schlippenbach J; Skurk C; Steendijk P; Riad A; Poller W; Schultheiss HP; Tschöpe C
Circ Heart Fail; 2011 Jan; 4(1):44-52. PubMed ID: 21075869
[TBL] [Abstract][Full Text] [Related]
37. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
Vanhoutte D; Schellings M; Pinto Y; Heymans S
Cardiovasc Res; 2006 Feb; 69(3):604-13. PubMed ID: 16360129
[TBL] [Abstract][Full Text] [Related]
38. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure.
Ichihara S; Noda A; Nagata K; Obata K; Xu J; Ichihara G; Oikawa S; Kawanishi S; Yamada Y; Yokota M
Cardiovasc Res; 2006 Feb; 69(3):726-35. PubMed ID: 16165109
[TBL] [Abstract][Full Text] [Related]
39. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart.
Heymans S; Schroen B; Vermeersch P; Milting H; Gao F; Kassner A; Gillijns H; Herijgers P; Flameng W; Carmeliet P; Van de Werf F; Pinto YM; Janssens S
Circulation; 2005 Aug; 112(8):1136-44. PubMed ID: 16103240
[TBL] [Abstract][Full Text] [Related]
40. A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensive rats.
Kong EK; Yu S; Sanderson JE; Chen KB; Huang Y; Yu CM
Eur J Pharmacol; 2011 May; 658(2-3):175-81. PubMed ID: 21371455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
